Risk factors and clinical outcomes of cytomegalovirus diseases in hematologic malignancy patients without hematopoietic stem-cell transplantation
© 2023. The Author(s), under exclusive licence to Springer-Verlag GmbH Germany, part of Springer Nature..
PURPOSE: This study aims to evaluate the risk factors and prognosis for CMV diseases in hematologic malignancy patients without hematopoietic stem-cell transplantation (HSCT).
METHODS: We performed a case-control study (1:2) between 2012 and 2022. Adults with pathologic-confirmed CMV diseases (n=60) among hematologic malignancy patients were matched and compared to whom without CMV disease.
RESULTS: Lymphoma was the most common underlying malignancy, and gastrointestinal tract involvement was the most common CMV disease. In the case group, high-dose steroid administration and transfusion within one month before diagnosis were higher (p<0.001). Steroid administration (aOR=5.78; 95% confidence interval: 1.25-26.68, p=0.024), red blood cell transfusion within one month (aOR=14.63; 2.75-77.76, p=0.002), low BMI (aOR=13.46, 2.07-87.45, p=0.006), and hypoalbuminemia (aOR=26.48, 5.93-118.17, p<0.001) were independent risk factors associated with CMV disease. The 30-day mortality was higher in the case group and CMV disease was significantly associated with all-cause mortality (aOR=14.41, 3.23-64.31, p<0.001).
CONCLUSION: In hematologic malignancy patients without HSCT, risk factors for CMV organ disease included high-dose steroid administration and RBC transfusion within one month, low BMI, and hypoalbuminemia. Overall mortality was significantly higher with CMV disease, and CMV disease occurrence was a significant risk factor for mortality.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2023 |
|---|---|
| Erschienen: |
2023 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:32 |
|---|---|
| Enthalten in: |
Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer - 32(2023), 1 vom: 22. Dez., Seite 56 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Yang, Jinyoung [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
CMV organ disease |
|---|
| Anmerkungen: |
Date Completed 26.12.2023 Date Revised 15.01.2024 published: Electronic Citation Status MEDLINE |
|---|
| doi: |
10.1007/s00520-023-08258-5 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM366243713 |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM366243713 | ||
| 003 | DE-627 | ||
| 005 | 20240116231955.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231227s2023 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1007/s00520-023-08258-5 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1261.xml |
| 035 | |a (DE-627)NLM366243713 | ||
| 035 | |a (NLM)38133709 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Yang, Jinyoung |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Risk factors and clinical outcomes of cytomegalovirus diseases in hematologic malignancy patients without hematopoietic stem-cell transplantation |
| 264 | 1 | |c 2023 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 26.12.2023 | ||
| 500 | |a Date Revised 15.01.2024 | ||
| 500 | |a published: Electronic | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a © 2023. The Author(s), under exclusive licence to Springer-Verlag GmbH Germany, part of Springer Nature. | ||
| 520 | |a PURPOSE: This study aims to evaluate the risk factors and prognosis for CMV diseases in hematologic malignancy patients without hematopoietic stem-cell transplantation (HSCT) | ||
| 520 | |a METHODS: We performed a case-control study (1:2) between 2012 and 2022. Adults with pathologic-confirmed CMV diseases (n=60) among hematologic malignancy patients were matched and compared to whom without CMV disease | ||
| 520 | |a RESULTS: Lymphoma was the most common underlying malignancy, and gastrointestinal tract involvement was the most common CMV disease. In the case group, high-dose steroid administration and transfusion within one month before diagnosis were higher (p<0.001). Steroid administration (aOR=5.78; 95% confidence interval: 1.25-26.68, p=0.024), red blood cell transfusion within one month (aOR=14.63; 2.75-77.76, p=0.002), low BMI (aOR=13.46, 2.07-87.45, p=0.006), and hypoalbuminemia (aOR=26.48, 5.93-118.17, p<0.001) were independent risk factors associated with CMV disease. The 30-day mortality was higher in the case group and CMV disease was significantly associated with all-cause mortality (aOR=14.41, 3.23-64.31, p<0.001) | ||
| 520 | |a CONCLUSION: In hematologic malignancy patients without HSCT, risk factors for CMV organ disease included high-dose steroid administration and RBC transfusion within one month, low BMI, and hypoalbuminemia. Overall mortality was significantly higher with CMV disease, and CMV disease occurrence was a significant risk factor for mortality | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a CMV organ disease | |
| 650 | 4 | |a Cytomegalovirus | |
| 650 | 4 | |a Hematologic malignancy | |
| 650 | 7 | |a Steroids |2 NLM | |
| 700 | 1 | |a Kang, Cheol-In |e verfasserin |4 aut | |
| 700 | 1 | |a Lee, Young Ho |e verfasserin |4 aut | |
| 700 | 1 | |a Ko, Jae-Hoon |e verfasserin |4 aut | |
| 700 | 1 | |a Huh, Kyungmin |e verfasserin |4 aut | |
| 700 | 1 | |a Cho, Sun Young |e verfasserin |4 aut | |
| 700 | 1 | |a Chung, Doo Ryeon |e verfasserin |4 aut | |
| 700 | 1 | |a Peck, Kyong Ran |e verfasserin |4 aut | |
| 700 | 1 | |a Jung, Chul Won |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer |d 1994 |g 32(2023), 1 vom: 22. Dez., Seite 56 |w (DE-627)NLM07487618X |x 1433-7339 |7 nnns |
| 773 | 1 | 8 | |g volume:32 |g year:2023 |g number:1 |g day:22 |g month:12 |g pages:56 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1007/s00520-023-08258-5 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 32 |j 2023 |e 1 |b 22 |c 12 |h 56 | ||